DizzyEX

Bringing vertigo into focus

DizzyEX, Inc. is a medical device company dedicated to improving the evaluation of vertigo and dizziness by capturing eye movement during an attack, at home, as it happens.

Technology

Reading the episode itself

Vertigo produces characteristic patterns of eye movement, and those patterns vary with the underlying cause. The difficulty is that attacks happen at home, at work, in the middle of the night, almost never in front of a clinician. By the time a patient is examined, the signs are gone, and the evaluation rests on how well they can recall and describe an experience that was, by its nature, disorienting. DizzyEX has designed a medical device that captures and analyzes eye movement patterns during an attack to identify the undelying cause of vertigo.

01

Ship

The device is shipped to the patient, ready to use wherever their attacks actually happen.

02

Record

Eye movements are recorded through the episode, without the patient having to act during an attack.

03

Return

Recorded data is analyzeed and sent back for clinical review, giving the care team the information they need to make an accurate diagnosis.

Why this work is important

Common, disabling, and persistently hard to diagnose

Vertigo is hard to convey to anyone who has not felt it, and it can be frightening. One moment you are fine. Then, without warning, the world starts spinning, balance becomes hard to hold, and nausea takes over. For some people it happens once and passes. For many others it returns over months or years, unsettling daily life and, at times, mental health along with it.

In a population based cohort study, roughly 8% of adults reported vertigo,1 and among U.S. adults aged 40 and older, an estimated 35% show evidence of vestibular dysfunction on balance testing, ranging from findings a person would never notice to symptoms that make ordinary days difficult.2 Taken together, the three conditions behind most recurrent vertigo, benign paroxysmal positional vertigo, vestibular migraine, and Ménière disease, carry an estimated $151 billion in annual costs in the United States, of which $48 billion is direct medical spending.3

The toll varies from person to person, but it can run deep. Among more than 4,000 patients in an international vertigo registry, nearly 70% had cut back their hours, 63% had lost days of work, and roughly one in ten had left or switched jobs because of it.4 Roughly half of patients referred to specialty dizziness clinics report missing work,5 and median sick leave runs close to a month.6 Many also report worsened quality of life and depressive symptoms,7 difficulty that can persist even after the dizziness itself is considered settled,89 and, over a decade, gradual declines in physical functioning and general health.10 For older adults, vestibular problems meaningfully raise the risk of falling.11

Despite that burden, identifying the cause, which is what makes effective treatment possible, remains difficult. Attacks happen away from the clinic, so the evaluation usually depends on what a patient can describe afterwards. Identifying the specific cause from this information can be particularly challenging because episodes arising from quite different causes can feel much the same from the inside.

References

  1. Hackenberg B, O'Brien K, Döge J, et al. Vertigo and its burden of disease: results from a population based cohort study. Laryngoscope Investigative Otolaryngology. 2023;8(6):1624-1630. doi:10.1002/lio2.1169
  2. Agrawal Y, Ward BK, Minor LB. Vestibular dysfunction: prevalence, impact and need for targeted treatment. Journal of Vestibular Research. 2013;23(3):113-117. doi:10.3233/VES-130498
  3. Jeong SS, Simpson KN, Johnson JM, Rizk HG. Assessment of the cost burden of episodic recurrent vestibular vertigo in the US. JAMA Otolaryngology Head & Neck Surgery. 2022. doi:10.1001/jamaoto.2022.3247
  4. Benecke H, Agus S, Kuessner D, Goodall G, Strupp M. The burden and impact of vertigo: findings from the REVERT patient registry. Frontiers in Neurology. 2013;4:136. doi:10.3389/fneur.2013.00136
  5. Neuhauser HK, Radtke A, von Brevern M, et al. Burden of dizziness and vertigo in the community. Archives of Internal Medicine. 2008;168(19):2118-2124. doi:10.1001/archinte.168.19.2118
  6. Zborayova K, Barrenäs ML, Granåsen G, Kerber K, Salzer J. Dizziness and vertigo sick leave before and after insurance restrictions: a descriptive Swedish nationwide register linkage study. BMC Public Health. 2024;24(1):2591. doi:10.1186/s12889-024-20119-2
  7. Molnár A, Maihoub S, Mavrogeni P, Tamás L, Szirmai Á. Depression scores and quality of life of vertiginous patients suffering from different vestibular disorders. European Archives of Oto-Rhino-Laryngology. 2022;279(11):5173-5179. doi:10.1007/s00405-022-07366-y
  8. Strobl R, Harajli S, Huppert D, Zwergal A, Grill E. Impact of episodic and chronic vestibular disorders on health related quality of life and functioning: results from the DizzyReg patient registry. Quality of Life Research. 2023;32(6):1717-1726. doi:10.1007/s11136-023-03345-w
  9. Han SY, Lee SY, Suh MW, Lee JH, Park MK. Quality of life, physical symptoms, and psychological symptoms according to the status of chronic vestibulopathy. PLoS One. 2024;19(11):e0312727. doi:10.1371/journal.pone.0312727
  10. Gopinath B, Tang D, Burlutsky G, Mitchell P. Ten year incidence, predictors and impact of dizziness and vertigo in community dwelling adults. Maturitas. 2024;180:107890. doi:10.1016/j.maturitas.2023.107890
  11. Hall CD, Herdman SJ, Whitney SL, et al. Vestibular rehabilitation for peripheral vestibular hypofunction: an updated clinical practice guideline from the Academy of Neurologic Physical Therapy of the American Physical Therapy Association. Journal of Neurologic Physical Therapy. 2022;46(2):118-177. doi:10.1097/NPT.0000000000000382
Who it is for

Who it could help

Health providers

Bring a record of the episode into the visit, so that referrals to subspecialty care can be better targeted and fewer patients are sent on without an answer.

Patients

Shorten the path to a diagnosis, so that treatment can begin sooner and fewer people cycle through repeat appointments describing the same episode.

Health systems

Support a consistent pathway for dizziness that does not depend on the availability of a vestibular subspecialist.

Payers

Address the repeat visits, repeat imaging, and trial treatments that accumulate while the underlying cause remains unidentified.

The opportunity

A precedent in cardiology

Cardiology faced a version of this problem with palpitations. An ECG taken in clinic is only informative if the arrhythmia happens to occur during the recording, which it often does not. Ambulatory monitoring addressed that by moving the recording out of the clinic and into the patient's ordinary week. It is now a well established part of cardiac care, and an estimated $8.5 billion category.

Dizziness has the same patient prevalence structure. The episode occurs away from the clinic, the findings resolve before they can be examined, and the assessment falls back on description. No comparable monitoring pathway exists.

35M

people seek care for vertigo each year across the United States and Europe

$17.5B

estimated total addressable market across the United States and Europe

About us

Our story

DizzyEX, Inc. is a medical device company dedicated to improving the evaluation of vertigo, dizziness, and balance disorders.

The company began in the clinic. The need was identified through Stanford's neuro-otology specialty clinic, where the attacks that would explain a patient's vertigo were rarely present by the time of the appointment. DizzyEX emerged from more than three years of Stanford based research by the founding team and is supported by Stanford affiliated translational funding including Neuroscience:Translate, Spectrum, Coulter, and E-Wear.

Our team

Danyang Fan
Danyang Fan
PhD
Chief Executive Officer

Stanford HCI, NSF Graduate Research Fellow. Previously Microsoft Research, Meta, Triple Ring Technologies, and GM.

Brad Liang
Brad Liang
MS
Chief Technology Officer

Previously PercuSense, Flotherm, and Medallia. Medtronic Presidential Award for CGM. More than 70 patents awarded.

Peter Santa Maria
Peter Santa Maria
MD, PhD
Chief Medical Officer

Professor and Chief of Otology and Neurotology at UPMC. Auration Biotech, Flotherm, and Earflo, a TIME 2025 Invention of the Year.

Steve Kargotich
Steve Kargotich
MBA, LLB, PhD
Chief Operating Officer

Executive Director of SPARK NS. Earflo, a TIME 2025 Invention of the Year.

Kristen Steenerson
Kristen Steenerson
MD
Scientific Board Chair

Founder of the Stanford Vestibular Neurology Center. Clinical Associate Professor of Otolaryngology and Neurology.

Contact us

Get in touch

We are glad to hear from anyone with an interest in this work. Tell us a little about yours and we will follow up.

Please do not submit personal health information through this form. DizzyEX cannot provide medical advice or respond to questions about individual symptoms.